BeStock  
Stocks › Biotechnology › CRSP

CRISPR Therapeutics CRSP

$39.10 +$0.17 (+0.44%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $39.50 +1.02%
Open$38.18
Prev close$38.93
Day range$38.15 – $40.17
Volume3.32M
Market cap$3.79B
P/E (TTM)–
Dividend yield–

CRSP Stock News

Headlines matching CRISPR Therapeutics or the CRSP ticker, most recent first.

  • Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Raises Target Price to $55 PositiveMarket news · 6 Aug 2026 · Direct mention
  • BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $82 NegativeMarket news · 6 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $60 to $110Market news · 5 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)TipRanks · 31 Aug 2026 · Direct mention
  • Evercore Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $76Market news · 31 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80Market news · 31 Aug 2026 · Direct mention
  • Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60Market news · 29 Aug 2026 · Direct mention
  • William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy RatingMarket news · 29 Aug 2026 · Direct mention
  • Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $55Market news · 10 Aug 2026 · Direct mention
  • BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $83Market news · 7 Jul 2026 · Direct mention
  • Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $110Market news · 2 Jul 2026 · Direct mention
  • Morgan Stanley Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $60Market news · 11 Jun 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)TipRanks · 11 Jun 2026 · Direct mention
  • Morgan Stanley Upgrades CRISPR Therapeutics(CRSP.US) to Hold Rating, Raises Target Price to $60 PositiveMarket news · 11 Jun 2026 · Direct mention
  • Wells Fargo Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $75Market news · 6 May 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on CRSP.

Sign in to join the discussion.

Scroll to Top